Findings of Research Misconduct, 38166-38167 [E6-10440]
Download as PDF
<![CDATA[
38166
Federal Register / Vol. 71, No. 128 / Wednesday, July 5, 2006 / Notices
editorial comments about certain data
items. The other agencies published a
separate Federal Register notice on June
19, 2006 (71 FR 35325) and will each
separately submit their SAR information
collection to OMB.
Several commenters suggested that
the agencies provide a test site for filing
electronic submissions. Due to time
constraints, FinCEN is unable to provide
a test site; however, respondents will
have a six-month transition period
before being required to use the revised
reporting form for submitting data.
Two commenters stated that the
overall burden estimate appeared to be
low even though it was increased from
thirty minutes to one hour. One
commenter specifically noted that the
burden estimate did not account for
regulatory compliance, fraud detection,
and mitigation. While important, these
regulatory requirements are outside the
scope of the burden calculation required
by the Paperwork Reduction Act. The
agencies, however, continue to welcome
comments from the industry and would
reevaluate and make adjustments to the
burden, as appropriate.
Several commenters expressed
concern over the new format of the
reporting form and whether it would
cause important information to be
omitted by respondents. The agencies
rearranged data items on the reporting
form, per law enforcement request, to
improve the usefulness of the data.
Also, additional clarifications were
included in the instructions to provide
respondents with better guidance on
how to submit the revised data.
Board of Governors of the Federal Reserve
System, June 28, 2006.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc. E6–10410 Filed 7–3–06; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RESERVE SYSTEM
rwilkins on PROD1PC63 with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
VerDate Aug<31>2005
19:34 Jul 03, 2006
Jkt 205001
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at https://www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than July 28, 2006.
A. Federal Reserve Bank of New
York (Anne McEwen, Financial
Specialist) 33 Liberty Street, New York,
New York 10045-0001:
1. The Toronto—Dominion Bank,
Toronto, Ontario, Canada; and TD
Banknorth Inc., Portland, Maine; to
acquire shares of Interchange Financial
Services Corporation, and thereby
indirectly acquire Interchange Bank,
both of Saddle Brook, New Jersey.
B. Federal Reserve Bank of St. Louis
(Glenda Wilson, Community Affairs
Officer) 411 Locust Street, St. Louis,
Missouri 63166-2034:
1. Cross County Bancshares, Inc.,
Wynne, Arkansas; to acquire 6.6 percent
of the voting shares of Pinnacle
Bancshares, Inc., and thereby indirectly
acquire Pinnacle Bank, both in
Bentonville, Arkansas.
2. Lonoke Bancshares, Inc., Lonoke,
Arkansas; to acquire 6.6 percent of the
voting shares of Pinnacle Bancshares,
Inc., and thereby indirectly acquire
Pinnacle Bank, both in Bentonville,
Arkansas.
3. Pinnacle Bancshares Inc.,
Bentonville, Arkansas; to become a bank
holding company by acquiring 100
percent of the voting shares of Pinnacle
Bank, Bentonville, Arkansas.
4. German American Bancorp, Inc.,
Jasper, Indiana; to acquire 100 percent
of the voting shares of German
American Bancorp, Jasper, Indiana (in
organization).
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Board of Governors of the Federal Reserve
System, June 28, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–10399 Filed 7–3–06; 8:45 am]
BILLING CODE 6210–01–S
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies;
Correction
This notice corrects a notice (FR Doc.
E6-9670) published on page 35423 of
the issue for Tuesday, June 20, 2006.
Under the Federal Reserve Bank of
Chicago, the entry for NRBC Holding
Corporation, Chicago, Illinois, is revised
to read as follows:
A. Federal Reserve Bank of Chicago
(Patrick M. Wilder, Assistant Vice
President) 230 South LaSalle Street,
Chicago, Illinois 60690-1414:
NRBC Holding Corporation, Chicago,
Illinois; to become a bank holding
company by acquiring 100 percent of
the outstanding shares of The National
Republic Bank of Chicago, Chicago,
Illinois.
Comments on this application must
be received by July 14, 2006.
Board of Governors of the Federal Reserve
System, June 29, 2006.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E6–10438 Filed 7–3–06; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Lingjie Zhao, University of Iowa:
Based on the investigation reports
drafted by the University of Iowa (UI)
and additional analysis conducted by
ORI in its oversight review, the U.S.
Public Health Service (PHS) found that
Lingjie Zhao, former Doctoral Student,
UI, engaged in research misconduct.
The research was supported by National
Cancer Institute (NCI), National
Institutes of Health (NIH), grant P01
CA66081.
E:\FR\FM\05JYN1.SGM
05JYN1
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 71, No. 128 / Wednesday, July 5, 2006 / Notices
PHS found that Ms. Zhao engaged in
research misconduct by falsifying
research records included in: (a) A
manuscript submitted for publication in
Cancer Research, (b) drafts of her work
reported in the laboratory, and (c) drafts
of her work reported to her dissertation
committee. Specifically, PHS found:
1. That Ms. Zhao darkened with a
marking device the thioredoxin (Trx)
band of Lanes 1 and 2 on the
autoradiographic film that was to
become part of Figure 9 of the
manuscript.
2. That Ms. Zhao (a) falsified this
same original film of the western blot by
darkening Lanes 1, 2, 4, and 5 with a
marking device at the origin of the gel
and (b) further falsified Figure 9 of the
Cancer Research manuscript by
claiming falsely that these marked
bands were thioredoxin reductase (TR)
untreated and with mismatch
oligodeoxynucleotide in the presence
and absence of tumor necrosis factor
alpha.
3. That Ms. Zhao falsified the
glutathione reductase (GR) activity data
in either Figure 4 or Figure 9 of the
Cancer Research manuscript (the data
are identical but stated to be from
entirely different experimental
conditions).
4. That Ms. Zhao falsified the actin
data in either Figure 4 or Figure 9 of the
Cancer Research manuscript or in the
experiments simultaneously using Prx
III-As and Phospholipid hydroperoxide
glutathione peroxidase-As reported in
slide presentations (the actin data are
identical under 3 entirely different
experimental conditions).
5. That Ms. Zhao falsified the
manganese superoxide dismutase
(MnSOD) data in either Figure 1A or
Figure 4 of the Cancer Research
manuscript (these MnSOD data are
identical while being clearly described
as coming from different experiments).
6. That Ms. Zhao falsified the MnSOD
data in Figure 2 of the Cancer Research
manuscript by enhancing with a
marking device Lanes 6 and 7,
mismatch and antisense Prx oligos at 3
days of incubation (unmarked, Prx III–
As decreased the expression of
MnSOD).
Ms. Zhao has entered into a Voluntary
Exclusion Agreement in which she has
voluntarily agreed, for a period of three
(3) years, beginning on June 3, 2006:
(1) To exclude herself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
VerDate Aug<31>2005
19:34 Jul 03, 2006
Jkt 205001
nonprocurement programs of the United
States Government as defined in the
debarment regulations at 45 CFR part
76;
(2) To exclude herself from serving in
any advisory capacity to PHS including,
but not limited, to service on any PHS
advisory committee, board, and/or peer
review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852. (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6–10440 Filed 7–3–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, Department of Health and
Human Services.
ACTION: Notices.
AGENCY:
SUMMARY: This notice announced the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) allow the proposed
information collection project:
‘‘Eisenberg Center Voluntary Customer
Survey Generic Clearance for the
Agency for Healthcare Research and
Quality.’’ In accordance with the
Paperwork Reduction Act of 1995,
Public Law 104–13 (44 U.S.C.
3506(c)(2)(A)), AHRQ invites the public
to comment on this proposed
information collection.
DATES: Comments on this notice must be
received by September 5, 2006.
ADDRESSES: Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, 540
Gaither Road, Room #5036, Rockville,
MD 20850.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from AHRQ’s Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ, Reports
Clearance Officer, (301) 427–1477.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
38167
SUPPLEMENTARY INFORMATION:
Proposed Project
‘‘Eisenberg Center Voluntary
Customer Survey Generic Clearance for
the Agency for Healthcare Research and
Quality.’’
AHRQ’s newly-established Eisenberg
Center is an innovative effort aimed at
improving communication of findings to
a variety of audiences (‘‘customers’’),
including consumers, clinicians, payers,
and health care policy makers. The
Eisenberg Center, one of three
components of AHRQ’s Effective Health
Care Program announced in September
2005, is directed through a contract by
the Oregon Health and Science
University, Department of Medicine,
located in Portland, Oregon. The
Eisenberg Center intends to employ the
latest survey research techniques to (1)
determine how well its products and
services are meeting customers’ current
and anticipated needs; (2) identify
problem areas with existing products
and services and determine what
improvements should be made to
improve these products and services;
and (3) identify and develop new
products and services.
To address customer requirements
and to evaluate current and future
AHRQ products and services, the
Eisenberg Center must periodically
determine how well the Eisenberg
Center products and services are
meeting customer’s’ current and
anticipated needs. Work conducted
under this clearance will improve the
products and services the Center
develops for AHRQ for a three year
period. The health care environment
changes rapidly and requires a quick
response from AHRQ to provide
appropriately refined products and
services. A generic clearance for this
work will facilitate AHRQ’s timely
response to customers’ needs.
Methods of Collection
Participation in survey testing will be
fully voluntary and non-participation
will have not affect on eligibility for, or
receipt of, future AHRQ health services
research support, on future
opportunities to participate in research
or to obtain informative research results.
Specific estimation procedures, when
used, will be described when we notify
OMB as to actual studies conducted
under the clearance.
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 71, Number 128 (Wednesday, July 5, 2006)]
[Notices]
[Pages 38166-38167]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-10440]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Lingjie Zhao, University of Iowa: Based on the investigation
reports drafted by the University of Iowa (UI) and additional analysis
conducted by ORI in its oversight review, the U.S. Public Health
Service (PHS) found that Lingjie Zhao, former Doctoral Student, UI,
engaged in research misconduct. The research was supported by National
Cancer Institute (NCI), National Institutes of Health (NIH), grant P01
CA66081.
[[Page 38167]]
PHS found that Ms. Zhao engaged in research misconduct by
falsifying research records included in: (a) A manuscript submitted for
publication in Cancer Research, (b) drafts of her work reported in the
laboratory, and (c) drafts of her work reported to her dissertation
committee. Specifically, PHS found:
1. That Ms. Zhao darkened with a marking device the thioredoxin
(Trx) band of Lanes 1 and 2 on the autoradiographic film that was to
become part of Figure 9 of the manuscript.
2. That Ms. Zhao (a) falsified this same original film of the
western blot by darkening Lanes 1, 2, 4, and 5 with a marking device at
the origin of the gel and (b) further falsified Figure 9 of the Cancer
Research manuscript by claiming falsely that these marked bands were
thioredoxin reductase (TR) untreated and with mismatch
oligodeoxynucleotide in the presence and absence of tumor necrosis
factor alpha.
3. That Ms. Zhao falsified the glutathione reductase (GR) activity
data in either Figure 4 or Figure 9 of the Cancer Research manuscript
(the data are identical but stated to be from entirely different
experimental conditions).
4. That Ms. Zhao falsified the actin data in either Figure 4 or
Figure 9 of the Cancer Research manuscript or in the experiments
simultaneously using Prx III-As and Phospholipid hydroperoxide
glutathione peroxidase-As reported in slide presentations (the actin
data are identical under 3 entirely different experimental conditions).
5. That Ms. Zhao falsified the manganese superoxide dismutase
(MnSOD) data in either Figure 1A or Figure 4 of the Cancer Research
manuscript (these MnSOD data are identical while being clearly
described as coming from different experiments).
6. That Ms. Zhao falsified the MnSOD data in Figure 2 of the Cancer
Research manuscript by enhancing with a marking device Lanes 6 and 7,
mismatch and antisense Prx oligos at 3 days of incubation (unmarked,
Prx III-As decreased the expression of MnSOD).
Ms. Zhao has entered into a Voluntary Exclusion Agreement in which
she has voluntarily agreed, for a period of three (3) years, beginning
on June 3, 2006:
(1) To exclude herself from any contracting or subcontracting with
any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States Government
as defined in the debarment regulations at 45 CFR part 76;
(2) To exclude herself from serving in any advisory capacity to PHS
including, but not limited, to service on any PHS advisory committee,
board, and/or peer review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852. (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6-10440 Filed 7-3-06; 8:45 am]
BILLING CODE 4150-31-P
